T*C
发帖数: 5492 | 1 Pfizer (PFE) says an experimental Alzheimer's treatment it's working on with
Johnson & Johnson (JNJ) unit Janssen Pharmaceuticals did not meet clinical
endpoints in a late-stage study. In the study, a certain class of patients
with mild-to-moderate Alzheimer's disease given an intravenous form of the
drug bapineuzumab did not fare any better in cognitive and functional
performance compared with those given a placebo. Elan (ELN), which holds a
49.9% equity interest in Janssen Alzheimer Immunotherapy, is taking a big
hit after hours: PFE -1.3%, JNJ -0.2%, ELN -16.8% |
|
